Arrayit Corp (OTCMKTS
CEO Rene Schena states, “We are delighted to report in-network status for our premium allergy testing services with a major commercial health insurer as a means of more easily serving, via their doctors, the nearly 60 million Americans with allergy and asthma symptoms. In-network access to our simple and convenient personalized healthcare solution for allergy detection and treatment fits squarely within our mission of improving health and wellness through greater awareness and preventative medicine.”
Arrayit Corp (OTCMKTS:ARYC) bills itself as a company that, according to management, “leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics.”
Arrayit sells its patented and proprietary microarray platform to scientists and doctors worldwide to accelerate biomedical research, to discover safer and more effective medicines, and to develop rapid and affordable testing methods to improve human health and well-being. Avant recently received Institutional Review Board (IRB) approval from the United States Food and Drug Administration (FDA) to validate ovarian cancer specimens pursuant to 510(k) approval of OvaDx(R), a pre-symptomatic ovarian cancer test that aids the monitoring of women diagnosed with ovarian cancer. OvaDx(R) is exclusively manufactured by Arrayit and will be marketed and sold by Avant upon FDA approval.
Arrayit provides it specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe.
According to company materials, “Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.”
Find out when $ARYC stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to company materials, ARYC recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, fulfilled an FDA clinical instrumentation contract, and received approval for in-store promotions by a major retailer.
The Apple Connection
Furthermore, the company has also hooked with an Apple provider to allow for technological innovation for allergy detection.
Holding a capital value in the market of $218.44M and a float of 608.89M, ARYC is working hard toward getting it allergy-testers to market and it is doing so with very little cash on the books. We will update the story again soon as further details emerge. For continuing coverage on shares of $ARYC stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $ARYC, either long or short, and we have not been compensated for this article.